A detailed history of Man Group PLC transactions in Nurix Therapeutics, Inc. stock. As of the latest transaction made, Man Group PLC holds 11,225 shares of NRIX stock, worth $304,758. This represents 0.0% of its overall portfolio holdings.

Number of Shares
11,225
Holding current value
$304,758
% of portfolio
0.0%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$12.02 - $21.3 $134,924 - $239,092
11,225 New
11,225 $234,000
Q4 2023

Feb 14, 2024

SELL
$4.25 - $10.71 $20,106 - $50,669
-4,731 Reduced 19.73%
19,248 $198,000
Q3 2023

Nov 14, 2023

BUY
$7.86 - $10.08 $188,474 - $241,708
23,979 New
23,979 $188,000

Others Institutions Holding NRIX

About Nurix Therapeutics, Inc.


  • Ticker NRIX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 47,147,800
  • Market Cap $1.28B
  • Description
  • Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies...
More about NRIX
Track This Portfolio

Track Man Group PLC Portfolio

Follow Man Group PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Man Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Man Group PLC with notifications on news.